Navigating NIH Funding During a Pandemic Patrick SF Bellgowan, Ph.D. Program Director for TBI Division of Neuroscience / NINDS / NIH [email protected]Linda Bambrick, Ph.D. Program Director for SCI Division of Neuroscience / NINDS / NIH [email protected]Thank you to the Organizers Olga N. Kokiko-Cochran, Ph.D. - NNS Council Member Grace Griesbach, Ph.D. - NNS President Sheilah Jewart - - NNS Exec Director NNS Leadership
21
Embed
Navigating NIH Funding During a Pandemic€¦ · Blueprint Neurotherapeutics Network (BPN) for small molecules. Development of small molecules. Provides investigators with access
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Navigating NIH Funding During a Pandemic
Patrick SF Bellgowan, Ph.D.Program Director for TBI
Olga N. Kokiko-Cochran, Ph.D. - NNS Council MemberGrace Griesbach, Ph.D. - NNS PresidentSheilah Jewart - - NNS Exec DirectorNNS Leadership
Navigating NIH Funding During a Pandemic
Coronavirus Disease 2019 (COVID-19): Information for NIH Applicants and Recipients of NIH FundingThe NIH is deeply concerned for the health and safety of people involved in NIH research, and about the effects on the biomedical enterprise in the areas affected by the HHS declared public health emergency for COVID-19. Due to the potential exceptional impact, we want to assure our recipient community that NIH will be doing our part to help you continue your research.
This is a rapidly evolving situation and we will provide updated guidance and information as it becomes available.
• There are excellent resources available online, we are here today to answer questions• Focus on NINDS• Links and resources will be made available• Questions welcome
• We continue to process applications and make awards
• We are conducting peer review meetings virtually
• We are offering administrative flexibilities in response to the effects of the pandemic on research
• We are working diligently to provide funding opportunities to support COVID-19 research
NIH is Open for Business
So you already have an award: progress reports, extensions, carry over requests, allowable expenses, milestones
• Progress report deadlines have not changed, do document any covid-19 pandemic impacts on resources and productivity as well as any foreseeable future challenges
• First year no-cost extensions can be still be automatically granted for awards that allow extensions
• It is possible more awardees will need to request approval for a second NCE—discuss with your program director and this is where documentation of impact in your progress reports may be helpful
• NIH is being flexible with carryover requests, discuss with your PD• NIH is being flexible about allowable expenses, e.g. salaries for staff—but some
administrative flexibilities expire at the end of September, consult your PD and https://grants.nih.gov/policy/natural-disasters/corona-virus/nih-omb-memo.htm
• Any award with milestones, e.g. IGNITE or SBIR will require negotiation with the PD
• PIs of awards, such as R01s, coming up for renewal need to consider whether their research project is best served by a NCE or a competitive renewal application
• For competitive renewals PIs should be aware that the following guidance has been provided to study section reviewers:
Reviewers should assume that problems arising from the COVID-19 pandemic will be resolved and complications related to COVID-19 should not affect their scores. Disregard temporary situations due to the COVID-19 pandemic, e.g. temporary declines in productivity, availability of key personnel, proposed patient populations, animal facility shutdowns, etc.
Guidance for peer reviewershttps://grants.nih.gov/sites/default/files/Coronavirus-update-Additional-Guidance-for-Peer-Reviewers.pdf
NIH has implemented a special exception to allow preliminary data as post submission materials beginning with due dates/on/after May 25, 2020:
• Preliminary data must be submitted 30 days before the study section meeting• AOR concurrence required• One page of preliminary data will be accepted for single component
applications or for each component of a multi-component application• Funding opportunity must allow preliminary data (i.e. does not explicitly
indicate preliminary data is not allowed)• Post-submission materials will not be accepted for applications for emergency
competitive revisions and urgent competitive revisions which undergo expedited review
• Check with your PD and SRO
Post-Submission Materials
Learn more: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-163.htmlInstructions for how to submit:https://grants.nih.gov/grants/guide/notice-files/NOT-OD-19-083.html
to facilitate the preclinical discovery and development of new therapeutic interventions for neurological disorders
The Mission of NINDS DTR
Blueprint NeurotherapeuticsNetwork (BPN) for small molecules
Development of small moleculesProvides investigators with access to consultants and contracts that provide discovery, preclinical development, and clinical trial support
Cooperative Research to Enable and Advance Translational Enterprises (CREATE) Bio and Devices
Development of biologics or Devices (including proteins, peptides, nucleic acids, gene and cell therapies)
Assay Development and Therapeutic Agent Identification and Characterization^ Pharmacodynamics and In vivo Efficacy Studies^ Development and Validation of Translational Model Systems for Drug Discovery*